Disclaimer

Testing Disclaimer

Alexander Perl, MD

Alexander Perl, MD Associate Professor of Medicine
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Dr. Alexander Perl is a member of the leukemia program at the Abramson Cancer Center of the University of Pennsylvania, where he is an Associate Professor of Medicine. His particular expertise is in FLT3 inhibition as a therapeutic strategy for acute myeloid leukemia, clinical trials, and mechanisms of resistance to tyrosine kinase inhibitors.

Last modified: July 8, 2020

Authored Items

How does quizartinib fit into the treatment paradigm of AML and what are the key aspects that clinicians need to know about this agent? How does quizartinib fit into the treatment paradigm of AML and what are the key aspects that clinicians need to know about this agent?
Alexander Perl, MD
Treatment Published on May 6, 2020
How are the results of the phase 3 ADMIRAL trial changing the treatment paradigm for salvage therapy of AML?How are the results of the phase 3 ADMIRAL trial changing the treatment paradigm for salvage therapy of AML?
Alexander Perl, MD
Treatment Published on May 6, 2020
What are the advantages and disadvantages of the different FLT3 inhibitors?What are the advantages and disadvantages of the different FLT3 inhibitors?
Alexander Perl, MD
Treatment Published on April 1, 2020
Third-generation FLT3 inhibitors in clinical developmentThird-generation FLT3 inhibitors in clinical development
Alexander Perl, MD
Treatment Published on October 18, 2018
What are the practical issues in FLT3 testing as it relates to PCR vs. NGS?What are the practical issues in FLT3 testing as it relates to PCR vs. NGS?
Alexander Perl, MD
Diagnosis Published on October 10, 2018
Key considerations when prescribing midostaurin with a strong CYP3A4 inhibitorKey considerations when prescribing midostaurin with a strong CYP3A4 inhibitor
Alexander Perl, MD
Treatment Published on September 20, 2018